These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34496076)

  • 1. Characterization of antiplatelet response to low-dose cangrelor utilizing platelet function testing in neuroendovascular patients.
    Holden DN; Entezami P; Bush MC; Field NC; Paul AR; Boulos AS; Yamamoto J; Dalfino JC
    Pharmacotherapy; 2021 Oct; 41(10):811-819. PubMed ID: 34496076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cangrelor dose titration using platelet function testing during cerebrovascular stent placement.
    Entezami P; Holden DN; Boulos AS; Paul AR; Field NC; Nourollahzadeh E; Yamamoto J; Dalfino JC
    Interv Neuroradiol; 2021 Feb; 27(1):88-98. PubMed ID: 32611215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet Function Testing to Guide Cangrelor Dosing in Patients with Temporary Mechanical Circulatory Support or as a Bridge to Procedure.
    Buck MM; Barry CI; Montepara CA; Verlinden NJ
    Clin Appl Thromb Hemost; 2024; 30():10760296241237228. PubMed ID: 38439661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
    Bowman S; Gass J; Weeks P
    Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study.
    Aguilar-Salinas P; Agnoletto GJ; Brasiliense LBC; Santos R; Granja MF; Gonsales D; Aghaebrahim A; Sauvageau E; Hanel RA
    J Neurointerv Surg; 2019 Apr; 11(4):347-351. PubMed ID: 30552167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
    Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
    Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet Therapy During Emergent Extracranial Internal Carotid Artery Stenting: Comparison of Three Intravenous Antiplatelet Perioperative Strategies.
    Delvoye F; Maier B; Escalard S; Labreuche J; Thion LA; Aknouche S; Hebert S; Redjem H; Smajda S; Ciccio G; Allard J; Sabben C; Obadia M; Maertens de Noordhout A; Olivot JM; Blanc R; Piotin M; Desilles JP; Mazighi M
    J Stroke Cerebrovasc Dis; 2021 Feb; 30(2):105521. PubMed ID: 33310073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
    Angiolillo DJ; Firstenberg MS; Price MJ; Tummala PE; Hutyra M; Welsby IJ; Voeltz MD; Chandna H; Ramaiah C; Brtko M; Cannon L; Dyke C; Liu T; Montalescot G; Manoukian SV; Prats J; Topol EJ;
    JAMA; 2012 Jan; 307(3):265-74. PubMed ID: 22253393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Use of Cangrelor With Heparin During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Who Require Cardiovascular Surgery: A Case Series.
    Gernhofer YK; Banks DA; Golts E; Pretorius V
    Semin Thorac Cardiovasc Surg; 2020 Winter; 32(4):763-769. PubMed ID: 31610233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures.
    Cagnazzo F; Radu RA; Derraz I; Lefevre PH; Dargazanli C; Machi P; Morganti R; Gascou G; Fendeleur J; Rapido F; Costalat V
    J Neurointerv Surg; 2023 Dec; 16(1):88-93. PubMed ID: 36922032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects during the transition between cangrelor and prasugrel.
    Schneider DJ; Seecheran N; Raza SS; Keating FK; Gogo P
    Coron Artery Dis; 2015 Jan; 26(1):42-8. PubMed ID: 25089928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study.
    Johnson BV; Horton ER; Domenico C; Nathan AS; Fanaroff AC; Acker MA; Kolansky DM
    J Invasive Cardiol; 2021 Dec; 33(12):E998-E1003. PubMed ID: 34817395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention.
    Linfante I; Ravipati K; Starosciak AK; Reyes D; Dabus G
    J Neurointerv Surg; 2021 Jan; 13(1):30-32. PubMed ID: 32414891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
    Angiolillo DJ; Schneider DJ; Bhatt DL; French WJ; Price MJ; Saucedo JF; Shaburishvili T; Huber K; Prats J; Liu T; Harrington RA; Becker RC
    J Thromb Thrombolysis; 2012 Jul; 34(1):44-55. PubMed ID: 22569899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
    JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.